Total Funding
89
71
Total FundingPost-IPO Equity raised
Growth Score
-2 pts
Heat Score
3 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
146788
PYC Therapeutics (ASX: PYC) is a development-stage biotechnology company pioneering a new generation of RNA therapeutics
Glenn Noronha: Chief Development OfficerPast Role: Clearside Biomedical, Executive Vice President, Research and Development
About the Company
PYC Therapeutics is a clinical-stage biotechnology company specializing in RNA-based therapies targeting genetic diseases. It leverages a proprietary delivery system using cell‑penetrating peptides (CPPs) conjugated to phosphorodiamidate morpholino oligomers (PMOs) to enhance cellular uptake. The company’s pipeline focuses on inherited conditions
affecting the eye, central nervous system, and kidney, including ongoing Phase 1 and natural history studies.
